2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors.
Dai, C., Li, D., Popovici-Muller, J., Zhao, L., Girijavallabhan, V.M., Rosner, K.E., Lavey, B.J., Rizvi, R., Shankar, B.B., Wong, M.K., Guo, Z., Orth, P., Strickland, C.O., Sun, J., Niu, X., Chen, S., Kozlowski, J.A., Lundell, D.J., Piwinski, J.J., Shih, N.Y., Siddiqui, M.A.(2011) Bioorg Med Chem Lett 21: 3172-3176
- PubMed: 21458257 
- DOI: https://doi.org/10.1016/j.bmcl.2011.01.002
- Primary Citation of Related Structures:  
3O64 - PubMed Abstract: 
TNF-α converting enzyme (TACE) inhibitors are promising agents to treat inflammatory disorders and cancer. We have investigated novel tartrate diamide TACE inhibitors where the tartrate core binds to zinc in a unique tridentate fashion. Incorporating (R)-2-(2-N-alkylaminothiazol-4-yl)pyrrolidines into the left hand side amide of the tartrate scaffold led to the discovery of potent and selective TACE inhibitors, some of which exhibited good rat oral bioavailability.
Organizational Affiliation: 
Department of Chemistry, Merck Research Laboratories, 320 Bent Street, Cambridge, MA 02141, USA. chaoyang.dai@merck.com